Research

Hormonal

GLP-1 receptor agonists are associated with reduced risks of various psychiatric disorders, including substance use disorders, suicidal ideation, and dementia, suggesting potential neuroprotective benefits beyond weight management.

While GLP-1RAs are primarily used for weight loss, emerging large-scale data suggests they may also reduce the risk of certain psychiatric conditions like dementia and substance use disorders. However, these benefits are observational, and more research is needed to confirm if GLP-1RAs directly cause these improvements or if other factors are involved.

ModerateQualifiesMEDIUM confidence
GLP-1RA use was linked to lower risks of substance-related disorders... reduced suicidal ideation, self-harm... and neurocognitive disorders... including dementia and Alzheimer’s disease.
Samantha Jacobson et al. · The Canadian Journal of Psychiatry · 2025

Why this rating

Based on large observational databases (Xie et al.) and preclinical models, but lacks direct RCT evidence for psychiatric outcomes in SPMI.

Source

GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness

Samantha Jacobson et al. · The Canadian Journal of Psychiatry · 2025

DOI 10.1177/07067437251386626

narrative_reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →